Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
₹167 Cr
P/E Ratio
--
P/B Ratio
-1.21
Industry P/E
54.87
Debt to Equity
-1.62
ROE
0 %
ROCE
-18.99 %
Div. Yield
0 %
Book Value
-63.95
EPS
-11.37
CFO
₹-114.48 Cr
EBITDA
₹-141.24 Cr
Net Profit
₹-228.57 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Krebs Biochemicals
| -16.91 | -0.49 | -16.91 | 8.22 | -23.35 | -1.90 | -- |
|
BSE Healthcare
| -7.68 | 6.11 | -2.04 | 19.11 | 18.77 | 22.70 | 8.84 |
|
BSE Small Cap
| -12.49 | 9.35 | -8.34 | 5.55 | 17.55 | 35.38 | 15.06 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Krebs Biochemicals
| 17.34 | -28.55 | -45.54 | 45.17 | 74.91 | -28.11 | -21.39 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 315.95 | 3,444.94 | 65.42 | 24.79 | |
| 775.95 | 3,932.25 | 35.64 | 9.22 | |
| 2,201.80 | 3,634.04 | 45.92 | 23 | |
| 613.95 | 4,325.38 | -- | 4.09 |
No Review & Analysis are available.
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include... androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. The company was incorporated in 1991 and is based in Visakhapatnam, India. Read more
Incorporated
1991
Chairman
R T Ravi
Managing Director
Jitendra Shah
Headquarters
Vishakhapatnam, Andhra Pradesh
Website
Looking for more details about Krebs Biochemicals & Industries Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Krebs Biochemicals & Industries Ltd stood at ₹ 185 Cr as on 31-Dec-24
The share price of Krebs Biochemicals & Industries Ltd is ₹77.27 (NSE) and ₹77.54 (BSE) as of 17-Apr-2025 IST. Krebs Biochemicals & Industries Ltd has given a return of -23.35% in the last 3 years.
Krebs Biochemicals & Industries Ltd has a market capitalisation of ₹ 167 Cr as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Krebs Biochemicals & Industries Ltd is -1.21 times as on 17-Apr-2025, a 148% discount to its peers’ median range of 2.52 times.
Since, TTM earnings of Krebs Biochemicals & Industries Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Krebs Biochemicals & Industries Ltd and enter the required number of quantities and click on buy to purchase the shares of Krebs Biochemicals & Industries Ltd.
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. The company was incorporated in 1991 and is based in Visakhapatnam, India.
The prominent promoters of Krebs Biochemicals & Industries Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Ipca Laboratories Limited |
49.65%
|
|
HEMALATHA RAVI |
12.48%
|
|
AVINASH RAVI |
9.93%
|
The chairman of the company is R T Ravi, and the managing director is Jitendra Shah.
There is no promoter pledging in Krebs Biochemicals & Industries Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,325
|
|
|
3,932
|
|
|
3,634
|
|
|
3,445
|
| Krebs Biochemicals & Industries Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-39.7
|
|
Net Margin(%)
|
-49.27
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Krebs Biochemicals & Industries Ltd was ₹-25 Cr.
₹-1.46
(
